̽»¨¾«Ñ¡

DEGREES

2006

Doctor of Philosophy (PhD), Department of Cell and Molecular Biology, ̽»¨¾«Ñ¡, Stockholm, Sweden
Thesis title: Proteolytic activation and biological functions of the novel PDGFs
URL: 
Main supervisor: Ulf Eriksson, co-supervisor: Ralf Pettersson

2000

Master of Science (MSc) in Molecular Biology, University of Umeå, Sweden. Including 1-year ERASMUS exchange at University of London, King’s College, UK 1996 – 1997 and Master Thesis Diploma Work, AstraZeneca R&D, Södertälje, Sweden, 1998.

CURRENT POSITION

2017– Researcher, Department of Medical Biochemistry and Biophysics, ̽»¨¾«Ñ¡, Stockholm, Sweden

PREVIOUS POSITIONS

2012–2017

Assistant Professor, Department of Medical Biochemistry and Biophysics, ̽»¨¾«Ñ¡, Stockholm, Sweden

2011            

Postdoctoral Researcher, Betsholtz Lab, Department of Medical Biochemistry and Biophysics, ̽»¨¾«Ñ¡, Stockholm, Sweden

2008-2010

Postdoctoral Researcher, Lawrence Lab, Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor MI, USA. Nov 2008 – Dec 2010.

2006-2008

Researcher, Ludwig Institute for Cancer Research Stockholm Branch, Stockholm, Sweden. Mar 2006 – Oct 2008.

2000-2006

PhD candidate, Ludwig Institute for Cancer Research Stockholm Branch, Stockholm, Sweden. Dec 2000 – Feb 2006.

1998-2000

Research scientist, AstraZeneca R&D, Södertälje, Sweden, Mar 1998 – Nov 2000.

Our research focuses on understanding the cellular and molecular signaling events occurring in the neurovascular unit (NVU) in ischemic stroke. We hypothesize that cerebrovascular remodeling and changes in blood brain barrier (BBB) integrity contributes to disease progression. We propose that targeting biological processes in the NVU, and ultimately restoring BBB integrity, has the potential to significantly improve outcome of disease and co-ordinate the injury-induced fibrotic response.

The long-term goal of our research is to identify novel targets in the cerebrovasculature that can be translated into clinical practice to improve treatment options of ischemic stroke.

To achieve our goal, we use experimental in vivo models of disease, primarily a photothrombotic model of ischemic stroke and 2P intravital imaging through a chronic cortical window, as well as unique blocking agents and genetic tools.